ReviewOxidative medicine and cellular longevity2017
Treatment of the Fluoroquinolone-Associated Disability: The Pathobiochemical Implications.
Review in Oxidative medicine and cellular longevity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies.BMC cardiovascular disorders · 2020Pooled it
- Fluoroquinolones and the Risk of Aortic Aneurysm or Aortic Dissection: A Systematic Review and Meta-Analysis.Cardiovascular & hematological agents in medicinal chemistry · 2019Pooled it
- Effects of fluoroquinolone antibiotics on extracellular matrix-related phenotypes in tendon cells.Scientific reports · 2026Article
- 18-β-glycyrrhetinic acid facilitates nuclear-mitochondrial communications to alleviate oxidative stress through HMGB1-cGAS-Mul1 axis in tendinopathy.Journal of translational medicine · 2026Article
- Fluoroquinolone-Associated Disability: A Rodent Model Reveals Transient Neuropsychiatric and Persistent Gastrointestinal Effects of Low-Dose Ciprofloxacin.Pharmaceuticals (Basel, Switzerland) · 2025Article
- An Unusual Manifestation of HSV-1 Uveitis Transforming into an Acute Iris Transillumination-like Syndrome with Pigmentary Glaucoma: A Reminder of Treatment Pitfalls in Herpetic Uveitis.Life (Basel, Switzerland) · 2025Article
- A prompt technique to identify fluoroquinolone antibiotics (FQs) residue in the environments.MethodsX · 2025Article
- Fluoroquinolones for Dermatologists: A Practical Guide to Clinical Use and Risk Management.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Understanding chronic inflammation: couplings between cytokines, ROS, NO, CaFrontiers in immunology · 2025Review
- Acute COVID-19 and LongCOVID syndrome - molecular implications for therapeutic strategies - review.Frontiers in immunology · 2025Review
- Ciprofloxacin's Structure Causing Fluoride-Related Toxicity: A Case Report.Current drug safety · 2025Article
- Article
- Antimicrobial Resistance and Sports: The Scope of the Problem, Implications for Athletes' Health and Avenues for Collaborative Public Health Action.Antibiotics (Basel, Switzerland) · 2024Review
- Review
- Lactoferricin B Combined with Antibiotics Exhibits Leukemic Selectivity and Antimicrobial Activity.Molecules (Basel, Switzerland) · 2024Article
- Fluoroquinolone-Associated Movement Disorder: A Literature Review.Medicines (Basel, Switzerland) · 2023Review
- Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?Pharmaceutics · 2023Review
- Antibiotic exposure is associated with decreased risk of psychiatric disorders.Frontiers in pharmacology · 2023Article
- Antibiotic Therapy and Athletes: Is the Mitochondrial Dysfunction the Real Achilles' Heel?Sports (Basel, Switzerland) · 2022Review
- The impact of oral ciprofloxacin on the structure and functions of rat gastric mucosa.Saudi journal of biological sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term fluoroquinolone-associated disability (FQAD) after fluoroquinolone (FQ) antibiotic therapy appears in recent years as a significant medical and social problem, because patients suffer for many years after prescribed antimicrobial FQ treatment from tiredness, concentration problems, neuropathies, tendinopathies, and other symptoms. The knowledge about the molecular activity of FQs in the cells remains unclear in many details. The effective treatment of this chronic state remains difficult and not effective. The current paper reviews the pathobiochemical properties of FQs, hints the directions for further research, and reviews the research concerning the proposed treatment of patients. Based on the analysis of literature, the main directions of possible effective treatment of FQAD are proposed: (a) reduction of the oxidative stress, (b) restoring reduced mitochondrion potential Δ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.